Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma
THBC-HSL2
1 other identifier
interventional
60
1 country
1
Brief Summary
The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2012
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
July 12, 2012
CompletedFirst Posted
Study publicly available on registry
July 16, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedSeptember 14, 2015
June 1, 2015
3.2 years
July 12, 2012
September 10, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response
biofeedback response will be monitored
within 10 min of exposure
Secondary Outcomes (1)
Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma
within 10 minutes of exposure
Study Arms (2)
hepatitis
EXPERIMENTALhepatitis B carriers patients
hepatocellular carcinoma patients
EXPERIMENTALhepatites B carriers patients with associated hepatocellular carcinoma
Interventions
Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
Eligibility Criteria
You may qualify if:
- hepatitis B carriers patients
- hepatitis B carriers patients with hepatocellular cancer patients
You may not qualify if:
- other tumor types
- other hepatitis types
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Sírio Libanês
São Paulo, São Paulo, 01308-050, Brazil
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Frederico P Costa, MD
Hospital Sirio-Libanes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending physician
Study Record Dates
First Submitted
July 12, 2012
First Posted
July 16, 2012
Study Start
April 1, 2012
Primary Completion
June 1, 2015
Study Completion
June 1, 2015
Last Updated
September 14, 2015
Record last verified: 2015-06